051 Clinical Serum Biomarker Profiling in TRuE-V1 and TRuE-V2 Vitiligo Studies After Treatment With Ruxolitinib Cream

Ruxolitinib cream was developed as a topical treatment for immune-mediated skin diseases, including vitiligo. is an equipotent inhibitor of Janus kinase (JAK) 1 and 2. Two identically designed randomized studies, TRuE-V1 (NCT04052425) TRuE-V2 (NCT04057573) were conducted in adolescent adult participants with nonsegmental vitiligo depigmentation over ≤10% total body surface area. This analysis examined whether observed pharmacodynamic effects primarily local or systemic due to the possibility absorption at site application. Serum samples biomarker collected baseline Weeks 12, 24, 40. The Week 24 visit corresponded primary endpoint efficacy end double-blind, vehicle-controlled period. Select (536 from 134 patients) analyzed changes expression relation plasma drug levels clinical parameters using Olink® Target 48 Cytokine panel. Across full panel, some serum biomarkers significantly changed after treatment. Nevertheless, none showed strong correlation concentrations steady state. Further, restricting highest ruxolitinib, which more stringent comparison, met our significance threshold P≤0.001. Next, relationship protein parameters, facial Vitiligo Area Scoring Index (F-VASI T-VASI, respectively), examined. All relationships, defined by repeated measures coefficient (Rrm), generally weak (Rrm<0.5); however, several analytes exhibited consistent statistically significant Rrm C-X-C chemokine ligands 9 10 (CXCL9 CXCL10). Together, these data suggest that ruxolitinib reflect improved condition are not correlated ruxolitinib.